Dear Editor, Cystic fibrosis (CF) is the most common life-limiting autosomal recessive hereditary disorder in Europe; the mean expected lifetime is approximately 35 years and has significantly increased over the last decades because of major advances in supportive treatment, especially treatment of infectious complications [1, 2]. In patients with CF, digestive tract cancers remain the majority of malignancies, whereas the risk for hematological neoplasias is low [5]. We hereby present a case of a patient with CF and newly diagnosed Hodgkin's Lymphoma (HL). Due to infectious issues and pulmonary comorbidity, the curative treatment of HL in this particular clinical setting is a challenge. A 21-year-old male patient with a history of CF was newly diagnosed with HL, Ann Arbor stage IIIb. Sputum samples repeatedly showed colonization with Pseudomonas aeruginosa, Staphylococcus aureus, Aspergillus fumigatus, and Mycobacterium abscessus that had already been present prior to the diagnosis of HL. The previous prophylactic antibiotic regimen at that time consisted of inhaled colistin (polymyxin E). To prevent infectious complications caused by A. fumigatus, Mycobacterium abscessus, gram-negative bacteria, or Pneumocystis jirovecii during chemotherapy-induced immunosuppression, the anti-infective prophylaxis was expanded to include voriconazole, clarithromycin, levofloxacinand trimethoprim/sulfamethoxazole, as well as regular prophylactic applications of G-CSF after chemotherapy to prevent neutropenia. Chemotherapy was based on a modified BEACOPPbasis regime without bleomycine due to the patient's impaired lung function. To maximize curative potential, eight cycles of “EACOPPbasis” were initially planned. However, due to recurring infectious complications of increasing length and severity (fever of unknown origin after the first course of chemotherapy preceding primarily lower respiratory tract infections with distinctly increasing pulmonary infiltrates), the cytotoxic treatment had to be delayed for a total of 42 days after only six cycles. Recurrent fever of unknown origin and documented infections (increased lung infiltrates) were treated with adequate antibiotic agents (e.g., imipenem, ceftazidime, cefepime, and aztreonam, intermittently supplemented with clindamycin or vancomycin). Microbiological sampling (blood culture and respiratory specimens) did not yield any additional pathogens. Despite intensive antimycobacterial treatment with clarithromycin, amikacin, imipenem, cefoxitin, moxifloxacin, linezolid, or tigecyclin [4], M. abscessus was repeatedly cultured from respiratory samples [3]. Chest CT scans revealed a moderate increase of preexisting lung infiltrates (Fig. 1). Restaging procedures including positron emission tomography CT showed a persisting complete remission after 17 months of follow-up care. Infectious complications, Stefan Baumann and Friederike Kuchler contributed equally to this work. S. Baumann : F. Kuchler :M. Reinwald :N. Hartel : W.-K. Hofmann :D. Buchheidt (*) Department of Haematology and Oncology, Hospital Mannheim University, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany e-mail: dieter.buchheidt@umm.de